• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Awake Craniotomy Challenges Center-Dependent Inoperability Designations in Diffuse Glioma Patients

by
November 12, 2026
in Cancer, Health
Reading Time: 3 mins read
0
Awake Craniotomy Challenges Center-Dependent Inoperability Designations in Diffuse Glioma Patients

Awake Craniotomy Challenges Center-Dependent Inoperability Designations in Diffuse Glioma Patients

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective investigation indicates that inoperability designations for diffuse glioma can vary between medical institutions, showing that selected patients previously deemed inoperable can safely undergo awake function-based craniotomy. Researchers evaluated clinical records spanning from 2011 to 2024 to determine whether individuals categorized as non-operable by outside medical facilities could achieve outcomes comparable to individuals initially considered candidates for surgical intervention. The findings suggest that surgical eligibility determinations may partly reflect institutional practices and surgical comfort levels rather than rigid anatomical barriers.

The study cohort comprised 448 adult patients who underwent awake function-based craniotomies for diffuse glioma treatment across the thirteen-year review window. Within this broader clinical population, 66 individuals, representing 14.7 percent of the total cohort, had previously received an inoperable designation from external medical centers prior to their evaluation. Investigators compared the clinical characteristics and procedural outcomes of these 66 patients directly against the larger group of patients who had been judged operable from the outset.

Baseline assessments revealed that individuals within the previously inoperable cohort presented with substantially greater preoperative clinical complexity across multiple key diagnostic measures. Patients in this group more frequently had histories of prior oncological treatments, exhibited focal neurological deficits before surgery, presented with significantly larger tumor volumes, displayed greater midline mass effect, and were more commonly diagnosed with IDH-wildtype glioblastoma. These baseline differences highlighted a cohort that presented heightened challenges prior to surgical intervention.

To evaluate operative safety and feasibility, researchers monitored intraoperative complications, surgical feasibility metrics, and postoperative functional recovery using analytical methods including propensity score matching and voxel-based lesion-symptom mapping. Crucially, no awake surgical procedures were aborted within the cohort of patients previously deemed inoperable. Both the unmatched and propensity score-matched analyses demonstrated that primary feasibility and safety endpoints did not significantly differ between the two patient groups.

Postoperative evaluation at six months confirmed comparable clinical and surgical results between patients previously declared non-operable and those initially considered operable. The comparative analysis demonstrated no significant divergence in intraoperative adverse events, overall surgery-related complications, six-month postoperative Karnofsky Performance Status scores, or six-month seizure control metrics. Furthermore, key oncological surgical markers, including the extent of surgical resection and final residual tumor volume measurements, remained consistent across both groups.

Voxel-based lesion-symptom mapping conducted by the research team failed to detect any independent anatomical predictor associated with an initial designation of inoperability. This analytical result indicates that physical tumor location alone did not provide an absolute, objective justification for excluding patients from awake function-based resection. Instead, decisions regarding operability appear to have been shaped by institutional factors and the specific technical approaches available at referring hospitals.

The investigators concluded that an external classification of inoperability should not automatically exclude selected patients from undergoing safe awake craniotomy when evaluated at high-volume surgical centers with specialized expertise in awake function-based procedures. Given that outcomes between conventional candidates and previously excluded individuals remained equivalent across functional and surgical endpoints, the study authors support the systematic consideration of second-opinion referrals for patients diagnosed with diffuse gliomas who are initially informed that their tumors cannot be surgically removed.

The investigators emphasized that the operational concept of non-operability across diffuse glioma cases remains poorly standardized across clinical practices. Rather than reflecting immutable surgical boundaries, such designations frequently mirror variations in institutional experience and procedural specialization. By reevaluating candidates within specialized surgical settings, surgical teams can reexamine traditional assumptions regarding which tumors are truly beyond operative management.

These observations carry direct clinical implications for treatment pathways following initial glioma diagnoses. Because awake function-based craniotomy achieved comparable safety and efficacy profiles even among patients presenting with larger tumor volumes, midline mass effect, and prior oncological treatments, obtaining a specialized second opinion can expand surgical eligibility for individuals initially advised that surgical resection is not an option.

Subject of Research: Awake function-based craniotomy outcomes in diffuse glioma patients previously designated inoperable

Article Title: Center-dependent “non-operability” in diffuse glioma: challenging assumptions through awake resection

Article References: Elia, A., Roux, A., Defrance, G., Debacker, C., Hudelist, B., Demasi, M., Moiraghi, A., Trancart, B., Seneca, M., Guibert, A., Chrétien, F., Zanello, M., & Pallud, J. (2026). Center-dependent “non-operability” in diffuse glioma: challenging assumptions through awake resection. Journal of Neuro-Oncology, 180(2), Article 45. https://doi.org/10.1007/s11060-026-05854-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05854-3

Keywords: diffuse glioma, awake craniotomy, neuro-oncology, neurosurgery, inoperability, second opinion, extent of resection, residual tumor volume, Karnofsky Performance Status, seizure control, IDH-wildtype glioblastoma, voxel-based lesion-symptom mapping, propensity score matching, surgical oncology, mass effect, functional mapping

News Source: Nathaniel Bowman. (November 12, 2026). Awake Craniotomy Challenges Center-Dependent Inoperability Designations in Diffuse Glioma Patients. Scienmag.

Tags: awake craniotomydiffuse gliomaextent of resectionfunctional mappingIDH-wildtype glioblastomainoperabilityKarnofsky Performance Statusmass effectNeuro-oncologyneurosurgerypropensity score matchingresidual tumor volumesecond opinionseizure controlSurgical Oncologyvoxel-based lesion-symptom mapping
Share12Tweet7Share2ShareShareShare1

Related Posts

Four Key Clinical Factors Associated With Heart Injury in Gastrointestinal Bleeding

Four Key Clinical Factors Associated With Heart Injury in Gastrointestinal Bleeding

November 17, 2026
Nanjing Hospital Study Finds 19.2 Percent HPV Positivity Among 39,335 Women

Nanjing Hospital Study Finds 19.2 Percent HPV Positivity Among 39,335 Women

November 17, 2026

Specialized EBI3-High Dendritic Cell Subset Identified in Rheumatoid Arthritis Synovial Fluid

November 17, 2026

Early Tildrakizumab Treatment Predicts Complete Psoriasis Clearance in Five-Year Italian Study

November 17, 2026

POPULAR NEWS

  • Four Key Clinical Factors Associated With Heart Injury in Gastrointestinal Bleeding

    Four Key Clinical Factors Associated With Heart Injury in Gastrointestinal Bleeding

    29 shares
    Share 12 Tweet 7
  • Nanjing Hospital Study Finds 19.2 Percent HPV Positivity Among 39,335 Women

    29 shares
    Share 12 Tweet 7
  • Specialized EBI3-High Dendritic Cell Subset Identified in Rheumatoid Arthritis Synovial Fluid

    29 shares
    Share 12 Tweet 7
  • Early Tildrakizumab Treatment Predicts Complete Psoriasis Clearance in Five-Year Italian Study

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Four Key Clinical Factors Associated With Heart Injury in Gastrointestinal Bleeding

Nanjing Hospital Study Finds 19.2 Percent HPV Positivity Among 39,335 Women

Specialized EBI3-High Dendritic Cell Subset Identified in Rheumatoid Arthritis Synovial Fluid

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.